15-008, £2,450 - Healthy men and non-childbearing-potential women needed for the study of a potential new medicine for treating pulmonary arterial hypertension (PAH). You must be 18-60 years old, and weigh more than 50 kg as a man or 45 kg as a woman. Smokers of up to 5 cigarettes per week are allowed. Vegetarians are not allowed. The study involves 4 periods of 3 night stays, 1 outpatient visit, and 1 follow up appointment. Ongoing until June 2017.
16-007, £2,100 - Healthy men needed for a study looking at the interaction between an experimental new medicine to treat influenza and an existing medication, Pitavastatin. You must be 18 to 60 years old, and weigh at least 50 kg. You must not have used nicotine products for the last 3 months, and you can't be of East Asian descendent. The study involves 2 sessions: 1 session of 2 nights' residence and a second session of 8 nights' residence, with 1 follow up appointment. Groups starting April/May 2017.
16-031, £1,450 - Healthy men needed for the study of a potential new treatment for conditions that affect mood, behaviour and movement. You must be aged 20 to 50, and a non-smoker for at least 6 months. The trial involves 2 screening visits and 2 sessions: a 1 night residence stay and a 6 night residence stay, and 1 follow up. The trial also involves 1 MRI and 3 PET scans. Groups starting in May 2017.
14-503, £1,250 + Travel expenses
Men and women with osteoarthritis of the knee needed for the study of a potential new treatment for osteoarthritis (OA) pain. You must be aged 18 to 80 and, if female, be of non-childbearing potential. You might not be eligible if you have certain medical conditions. The trial involves 4 screening visits (including an x-ray and an MRI), 2 nights residence stay, and 4 to 6 outpatient visits. Starts in May-June 2017.
16-503, £4,000 - People with mild allergic asthma needed to assess if a potential new medicine changes the body's response to allergens. You must be 18-65 years old, and a non-smoker for at least six months. You must only use a short-acting reliever such as Ventolin to control your asthma. If female, you must be postmenopausal for at least 12 months, or have had a hysterectomy, tubal ligation, or removal of your ovaries. The trial involves up to 22 outpatient visits, and possibly up to 4 overnight stays, over the course of about 6 months.
16-504, Up to £450 - Men and women with Crohn's disease needed for a study in which we aim to locate areas of inflammation in the bowel accurately, and see how much inflammation there is. You must be at least 20 years old, and not have any other gastrointestinal problems. The trial involves 2 outpatient visits over 1 month, and includes CT and PET scans. Ongoing until September 2017.
16-505, (Pree-screen) £60 - Healthy men and women needed for the study of a potential new treatment that might improve the appearance of acne scars. You must be aged 18 to 55 and have rolling-type acne scars. The first part of this study involves 1 outpatient visit about 3 hours long in which we'll assess your acne scars and we'll photograph them.
16-505, (Main Study) £2,000 - Healthy men and women needed for the study of a potential new treatment that might improve the appearance of acne scars. You must be aged 18 to 55 and have rolling-type acne scars. The study involves 7 outpatient visits over a 7 month period. Ongoing until June 2017,
16-509, £150 + Reasonable travel expenses - Men and women with stable COPD needed for a study to look at the errors and preferences when learning to use various combinations of inhalers. The inhalers in the study contain a dummy medicine, not COPD medicine. You must be at least 40 years old, and either a regular smoker who has smoked for several years, or an ex-smoker who hasn't smoked in the last 3 months. You must use inhalers that are not capsule-based, such as Symbicort or Seretide, to treat your COPD, and have done so consistently for at least 4 weeks. The trial consists of 1 outpatient visit only. Ongoing until June 2017.
The ethics committee and the Medicines and Healthcare products Regulatory Agency have approved the studies.